Argenta Discovery in research agreement with Aventis Pharmaceuticals
UK-based Argenta Discovery has entered into a new fee-for-service research agreement with US company Aventis Pharmaceuticals, of Bridgewater, NJ.
UK-based Argenta Discovery has entered into a new fee-for-service research agreement with US company Aventis Pharmaceuticals, of Bridgewater, NJ.
According to the three-year agreement, Aventis and its worldwide affiliates will be able to order research services that draw on Argenta's entire complement of chemical and biological research capabilities, including compound and library synthesis, medicinal chemistry, computer-aided drug design, biochemical screening, assay development, cellular screening and in vitro pharmacokinetics.
'Aventis has been an important and valued partner for Argenta since the company was founded in August 2000, said Dr Anthony Baxter, Argenta's ceo. 'We are extremely pleased that our relationship continues.'